The AlfaCare program, “Care and Resources to live with the Alpha-1 Antitrypsin Deficit (AATD)” has taken place at the Torrecárdenas Hospital in Almería. It is a comprehensive program of accompaniment and personalized support, created in collaboration with the Association of Alfa-1 Spain, which offers training, emotional support and support to patients affected by AATD through […]
Alfacare Workshop Almería 2020 Read More »
Our center has started to include patients in the EARCO (European Alpha-1 Research Collaboration). EARCO is a pan-European network committed to promoting clinical research and education in alpha-1 antitrypsin deficiency (AATD). The core project is the Pan-European AATD Registry, a collaboration that will provide real-world longitudinal data for AATD patients. EARCO has a global vision to
EARCO (European Alpha-1 Research Collaboration) Read More »
Grifols launches AlphaID ™, its free oral test that allows the diagnosis of most of the genetic variants that cause alpha-1 antitrypsin deficiency (AATD). AlphaID ™ makes it easy for clinicians to diagnose AATD, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD). Read more
Grifols Launches AlphaID ™ Read More »
The meeting of the Committee of the Spanish Registry of Patients with Alpha-1 Antitrypsin Deficiency (REDAAT) took place in Lisbon within the framework of the “AATD Experts Forum Iberia, Alpha-1 antitrypsin: A look to the future”, held in Lisbon and which has brought together experts from Spain and Portugal. Dr. Casas has participated in the
AATD Experts Forum Iberia 2019 Read More »
This document, coordinated by Drs. Francisco Casas (Coordinator of the Andalusian Alpha-1 Center in Granada) and José Antonio Quintano (Spanish Society of Primary Care Physicians – SEMERGEN) have the following objectives: 1) to improve the knowledge of COPD by DAAT by Primary Care. 2) sensitize the family doctor about the importance of early diagnosis 3)
Alpha-1 challenges and needs Coordinators: Alejandra Rey, Michael Campos y Francisco Casas Madrid has been the headquarters of the 1st Ibero-Latin American Forum on Alpha-1 antitrypsin deficiency, which has brought together more than 30 professionals from Argentina, Brazil, Colombia, Ecuador, Peru, Uruguay, Chile, Venezuela and Spain, committed to promoting research clinical and education in alpha-1
1st Iberolatinoamerican Forum on Alpha-1 antitrypsin deficiency Read More »
This monograph provides a complete and up-to-date description of the AATD. It covers basic biology, genetics, laboratory diagnosis and the main organic manifestations; describes the clinical presentation of the AATD in adults and children; and features chapters on genetic counseling, patient opinions, and future therapies. The content has been designed to meet the needs of
ERS Alpha-1 Antitrypsin Deficiency Monograph Read More »
The San Cecilio University Hospital has hosted the workshop “Learning to live with the AATD”, developed by Doctor Francisco Casas Maldonado, also coordinator of the Aldaluz Alfa-1 Center. Professionals from the Pulmonology Service of this hospital, located in the Health Technology Park, have participated, together with professionals from psychology and physiotherapy, in this workshop, which
During the 52nd Congress of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), held in Santiago de Compostela (June 13 to 16, 2019), the 1st theoretical-practical course on alpha-1 antitrypsin deficiency ( AATD). This course, organized by SEPAR Training and the Spanish Registry of Patients with Alpha-1 Antitrypsin Deficiency (REDAAT), has been coordinated by
1st SEPAR theoretical-practical course on alpha-1 antitrypsin deficiency Read More »
Clinical session of the Pneumology Service of the HU San Cecilio de Granada: How to diagnose easily and early in Primary Care. AlphaKit® and Progenika-REDAAT Diagnostic Circuit. Granada, June 11, 2019. Day Hospital clinical session to update protocols for the administration of biological products (alpha-1 antitrypsin and gammaglobulins) and monoclonal ones in severe asthma to
